BIODESIX INC Stock Price, News & Analysis

Biodesix (Nasdaq: BDSX) announced new findings from the Nodify XL2® proteomic test at the CHEST 2022 Annual Meeting, showcasing its effectiveness in evaluating the malignancy risk of pulmonary nodules. Data from the ORACLE study indicates the test performs equally well for nodules identified through lung cancer screenings and incidental findings. With the expansion of eligibility for lung cancer screening in the U.S., the test could help reduce unnecessary biopsies for benign nodules. The presentations highlight the role of blood-based testing in more accurate risk stratification.

Biodesix (BDSX) reported strong preliminary results for Q3 2022, with estimated total revenues between $10.6 million and $11.2 million, marking a 62% to 71% increase from Q3 2021. Core lung diagnostic testing revenues surged 96% to 103%, reaching $8.9 million to $9.2 million. Meanwhile, COVID diagnostic revenues saw significant growth, but are expected to decline due to contract expirations. The company maintains a strong cash position of $15.2 million as of September 30, 2022.

Biodesix (NASDAQ: BDSX), a leader in data-driven diagnostic solutions for lung disease, announced CEO Scott Hutton will participate in two investor conferences. The Morgan Stanley 20th Annual Global Healthcare Conference is on September 13, 2022, featuring a fireside chat at 9:10 a.m. ET. The H.C. Wainwright 24th Annual Global Investment Conference runs from September 12-14, 2022. Biodesix specializes in non-invasive tests for lung diseases, leveraging advanced AI technology to provide rapid and accurate diagnostic solutions.

Biodesix reported Q2 2022 financial results showing a 52% increase in core lung diagnostic revenue, totaling $7.3 million, compared to the same period in 2021. The overall revenue was $11.0 million, an 8% decline due to decreased COVID-19 testing. The company has received Medicare coverage for its Nodify CDT® test, enhancing long-term margins. Operating expenses rose 21% to $18.6 million, with a net loss of $15.8 million. Biodesix reaffirms its 2022 revenue outlook of $37.5 million to $39.5 million.

Biodesix, a prominent diagnostic solutions company specializing in lung diseases, announced that CEO Scott Hutton will present at the Canaccord Genuity 42nd Annual Growth Conference, scheduled for August 10, 2022, at 3:00 PM ET in Boston. The event will be available for live streaming on Biodesix's website. The company is known for its innovative diagnostic tests, including the Nodify Lung® nodule risk assessment and IQLung™ strategies for lung cancer, aiming to expedite treatment decisions. Biodesix also launched COVID-19 diagnostic tests, responding to the ongoing pandemic.

Biodesix, Inc. (BDSX) has announced promising results from a retrospective analysis of its VeriStrat proteomic test presented by Dr. Young Kwang Chae at the IASLC 2022 World Conference on Lung Cancer in Vienna. This analysis focused on patients with advanced-stage non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICIs) and highlighted that the test effectively predicts Progression Free Survival (PFS) and Overall Survival (OS) in patients with low or negative PD-L1 expression.

Biodesix, a diagnostic solutions company focusing on lung disease, will release its Q2 financial results on August 4, 2022, before trading begins. A conference call will take place at 8:00 a.m. ET for a financial discussion and business update. The company's non-invasive tests, such as Nodify Lung and IQLung, aim to improve lung disease diagnostics and treatment decisions. Biodesix utilizes advanced AI for diagnostic solutions and has expanded its testing portfolio in response to the COVID-19 pandemic.

Biodesix, Inc. (Nasdaq: BDSX) announced Medicare coverage for its Nodify CDT® lung nodule test, a significant milestone for lung nodule management. This test is part of Biodesix’s Nodify Lung® Nodule Risk Assessment strategy, which also includes the Nodify XL2® test. Both tests assist physicians in determining whether lung nodules are likely malignant or benign. With all five blood-based diagnostic tests now covered by Medicare, Biodesix aims to enhance patient access and expedite treatment decisions, crucial for lung cancer care.